Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -40.98M | -5.85M | -8.94M | -7.11M | -7.34M |
| Total Depreciation and Amortization | 0.00 | 0.00 | 4.00K | 59.00K | 52.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 37.13M | 508.00K | 326.00K | 150.00K | 448.00K |
| Change in Net Operating Assets | -964.00K | 1.52M | 223.00K | 1.63M | -3.55M |
| Cash from Operations | -4.81M | -3.82M | -8.39M | -5.27M | -10.39M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 0.00 |
| Cash Acquisitions | -- | -- | -- | -- | -96.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Investing | -- | -- | -- | -- | -96.00K |
| Total Debt Issued | -- | -- | -- | -- | 15.79M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.00K | -- | 18.26M | -- | -- |
| Repurchase of Common Stock | -- | -7.48M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 7.03M | -- | -- | -- |
| Cash from Financing | 1.00K | -446.00K | 18.26M | -- | 15.79M |
| Foreign Exchange rate Adjustments | -1.00K | 0.00 | 1.00K | -- | -63.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.81M | -4.27M | 9.88M | -5.27M | 5.24M |